Abstract 1802
Background
Targeting programmed cell death-1 receptor (PD-1) or its ligand PD-L1 has failed to provide durable clinical benefit for a majority of patients with solid carcinomas. Recent preclinical and clinical data suggests that addition of the IL-15 superagonist N-803 improves response rates to anti-PD-1 or anti-PD-L1 therapy. Thus, we hypothesized that N-809, a novel bifunctional agent comprised of N-803 fused to two single chain anti-PD-L1 variable region domains, would promote potent anti-tumor efficacy and immune activation in murine models of solid carcinomas.
Methods
The functionality of the N-809 components was examined in vitro. Anti-tumor efficacy of N-809 versus a clinically relevant dose of N-803 + anti-PD-L1 was assessed using murine MC38 colon and 4T1 triple negative breast tumor models. The immune-mediated mechanism of N-809 was examined in spleen and tumor using comprehensive flow-based analyses and functional assays. Serum cytokine levels were also measured. Finally, effects on tumor gene expression were examined using Nanostring. Nant biosciences provided N-809 as per Cooperative Research and Development Agreement with NCI.
Results
In vitrostudies confirmed that both components of N-809 were functional. N-809 drastically reduced MC38 tumor burden leading to increased survival and significantly reduced spontaneous lung metastasis of 4T1 tumors. In both tumor models, N-809 had improved efficacy versus a clinically relevant dose of N-803 + anti-PD-L1. In the MC38 model, N-809 increased serum levels of IFNg, TNFa, and IL-10. Depletion studies revealed that CD8+T and NK cells are required for the anti-tumor efficacy of N-809. The immune analysis showed enhanced CD8+ T and NK cell tumor infiltration, activation, and function. To determine the mechanism of the increased CD8 and NK cell infiltration, analyses were performed to examine tumor chemokines and inhibition of immune cell migration. Gene analysis revealed changes in chemokines, chemokine receptors, and immune response genes.
Conclusions
N-809 has anti-tumor efficacy in two murine carcinoma model mediated by increasing the number, activation, and function of CD8+ T cells and NK cells.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Funding
Nant Bioscience.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2664 - Phase (Ph) II study of MBG453 + spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy
Presenter: Nicholas Mach
Session: Poster Display session 3
Resources:
Abstract
1285 - Preliminary results of STELLAR-001, a dose escalation phase I study of the anti-C5aR, IPH5401, in combination with durvalumab in advanced solid tumors.
Presenter: Christophe Massard
Session: Poster Display session 3
Resources:
Abstract
3808 - GOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis
Presenter: Pierpaolo Correale
Session: Poster Display session 3
Resources:
Abstract
5677 - Immune correlates in peripheral blood samples in a preoperative window of opportunity randomized trial of nivolumab with or without tadalafil in resectable squamous cell carcinoma of the head and neck (SCCHN)
Presenter: Larry Harshyne
Session: Poster Display session 3
Resources:
Abstract
4854 - Phase 1 evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies
Presenter: John Powderly
Session: Poster Display session 3
Resources:
Abstract
4344 - Phase 1 Trial of CV301 in Combination with Anti-PD-1 Therapy in Non-squamous NSCLC
Presenter: Arun Rajan
Session: Poster Display session 3
Resources:
Abstract
4555 - Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumors: preliminary results from the hepatocellular carcinoma (HCC), NSCLC, bladder cancer, & MSI-H cohorts
Presenter: Henry Conter
Session: Poster Display session 3
Resources:
Abstract
3012 - Excellent CBR and Prolonged PFS in Non-Squamous NSCLC with Oral CA-170, an Inhibitor of VISTA and PD-L1
Presenter: Vivek Radhakrishnan
Session: Poster Display session 3
Resources:
Abstract
2536 - Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers
Presenter: Christophe Le Tourneau
Session: Poster Display session 3
Resources:
Abstract
1845 - Induction of tumor-infiltrating functional CD8 positive cells and PD-L1 expression in esophageal cancer by S-588410
Presenter: Takashi Kojima
Session: Poster Display session 3
Resources:
Abstract